Karyopharm Therapeutics (KPTI) Other Non Operating Income (2013 - 2025)

Karyopharm Therapeutics has reported Other Non Operating Income for 13 years, with the latest figure at $152000.0 in Q4 2025.

• For the quarter ending Q4 2025, Other Non Operating Income fell 98.5% year-over-year to $152000.0; the trailing twelve-month figure through Dec 2025 stood at $17.8 million (down 69.79% YoY), and the FY2025 full-year result was $152000.0, down 99.46% from the prior year.
• Other Non Operating Income for Q4 2025 stood at $152000.0, up from -$2.2 million in the prior quarter.
• The five-year high for Other Non Operating Income was $44.7 million in Q2 2024, with the low at -$2.2 million in Q2 2025.
• Historically, Other Non Operating Income has averaged $4.2 million across 5 years, with a median of $79500.0 in 2022.
• Annual changes were most pronounced in 2021 — Other Non Operating Income sank 344.0% — and 2025, when it jumped 10014.29%.
• Karyopharm Therapeutics' Other Non Operating Income stood at -$478000.0 in 2021, then jumped by 114.64% to $70000.0 in 2022, then jumped by 107.14% to $145000.0 in 2023, then jumped by 6875.17% to $10.1 million in 2024, then slumped by 98.5% to $152000.0 in 2025.
• The last three Other Non Operating Income figures came in at $152000.0 (Q4 2025), -$2.2 million (Q2 2025), and $19.8 million (Q1 2025), per Business Quant data.